News | August 06, 2008

First U.S. Clinical Trial Implant of DuraHeart LVAS Performed

August 6, 2008 - The first U.S. implant of Terumo Heart Inc.’s DuraHeart Left Ventricular Assist System (LVAS) took place on July 30 at the University of Michigan Cardiovascular Center in Ann Arbor.

National Co-Principal Investigator for the DuraHeart U.S. Pivotal Trial, Francis Pagani, M.D., Ph.D., performed the surgery. DuraHeart is reportedly the world's first third-generation LVAS combining a centrifugal pump with a magnetically levitated impeller to enter clinical trials in the U.S.

"The DuraHeart gives us a new, third-generation option for patients with advanced heart failure who need help to allow them to survive until they can receive a heart transplant," said Dr. Pagani, who leads the U-M Center for Circulatory Support.

The U.S. patient represents the 71st patient worldwide since the DuraHeart European investigational trials began in 2004, according to Terumo. In clinical results as of July 31, 2008, patient support averaged 223 days with cumulative support of 43 years. The longest ongoing patient support is over three years.
The DuraHeart LVAS Pivotal Trial is a multicenter, prospective, non- randomized study of 140 patients and will include up to 40 centers. The device is intended to provide cardiac support for patients awaiting transplant who are at risk of death due to end-stage left ventricular heart failure. Yoshifumi Naka, M.D., Ph.D., from Columbia Presbyterian Hospital in New York, will serve as the National Co-Principal Investigator with Dr. Pagani.

In addition to the U.S. trial, Terumo Heart is expected to initiate clinical trials in Japan this year.
DuraHeart is limited to investigational use only in the U.S., and is CE marked in Europe.

For more information: www.terumoheart.com/

Related Content

Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD)| October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD)| September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD)| June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD)| May 05, 2017
May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist De
Videos | Ventricular Assist Devices (VAD)| April 14, 2017
A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at
Henry Ford Hospital, Detroit Cardiogenic Shock Initiative, Impella pump, ACC.17 clinical study
News | Ventricular Assist Devices (VAD)| April 03, 2017
Hospitals can dramatically increase heart attack survival rates in patients suffering cardiogenic shock by providing...
Metro Detroit cardiologists, increased heart attack survival rate, Impella heart pump, Detroit Cardiogenic Shock Initiative
News | Ventricular Assist Devices (VAD)| March 09, 2017
Metro Detroit cardiologists from five health systems have joined together to increase residents’ survival rate from...
Impella 2.5 heart pump, high-risk PCI, HRPCI, acute kidney injury risk, AKI, Circulation Research study, Abiomed
News | Ventricular Assist Devices (VAD)| March 09, 2017
A new study published in Circulation Research finds use of hemodynamic support with the Impella 2.5 heart pump during...
James Ward, LVAD surgery, left ventricular assist device, UAB, University of Alabama at Birmingham
News | Ventricular Assist Devices (VAD)| March 08, 2017
Congestive heart failure patients at the University of Alabama at Birmingham (UAB) now have reason for optimism with a...
Overlay Init